环磷酰胺联合泼尼松治疗风湿免疫系统疾病的临床对照研究

在线阅读 下载PDF 导出详情
摘要   【摘 要】目的:分析环磷酰胺联合泼尼松治疗风湿免疫系统疾病的临床疗效对照。方法:选择 2017年 2月 -2018年 8月我院接受的 100例风湿免疫系统疾病案例作为研究对象,随机分为甲组和乙组,分别实施的是泼尼松和环磷酰胺联合泼尼松治疗,治疗后对结果对比。结果:对两组患者的治疗总有效率分析,乙组和甲组的有效人数分别是 45例和 35例,总有效率分别是 90%和 70%。对两组患者的并发症现象分析,甲组和乙组不良不反应率分别是 14%和 6%,乙组的发生几率低于甲组。结论:对于疗风湿免疫系统疾病案例实施环磷酰胺联合泼尼松治疗,整体效果突出,能满足患者的要求。    【关键词】环磷酰胺 ;泼尼松 ;风湿免疫系统疾病 ;效果分析    [Abstract] Objective: to analyze the clinical efficacy of cyclophosphamide combined with prednisone in the treatment of rheumatic immune system diseases. Methods: 100 cases of rheumatic immune system diseases accepted by our hospital from February 2017 to August 2018 were randomly divided into two groups: group A and group B, which were treated with prednisone and cyclophosphamide combined with prednisone respectively, and the results were compared after treatment. Results: according to the analysis of the total effective rate of the two groups, the effective number of patients in group B and group A were 45 and 35 respectively, and the total effective rate was 90% and 70% respectively. The incidence of adverse reactions in group A and group B was 14% and 6%, respectively. The incidence of adverse reactions in group B was lower than that in group A. Conclusion: cyclophosphamide combined with prednisone is effective in the treatment of rheumatic and immune system diseases.
出处 《世界复合医学》 2020年2期
关键词
出版日期 2020年04月19日(中国期刊网平台首次上网日期,不代表论文的发表时间)